期刊文献+

用含硼替佐米的联合化疗方案治疗多发性骨髓瘤的效果及安全性探析 被引量:4

下载PDF
导出
摘要 目的 :探讨用含硼替佐米的联合化疗方案治疗多发性骨髓瘤的效果及安全性。方法 :将2015年6月至2018年1月期间甘肃省定西市人民医院收治的82例多发性骨髓瘤患者分为试验组(n=41)和对照组(n=41)。这些患者入院后,均为其使用常规的化疗方案进行化疗。在此基础上,为试验组患者使用硼替佐米进行化疗。然后比较两组患者接受化疗的效果及不良反应的发生率。结果 :试验组患者接受化疗的总有效率高于对照组患者(P <0.05),其不良反应的发生率低于对照组患者(P <0.05)。结论 :用含硼替佐米的联合化疗方案治疗多发性骨髓瘤的效果及安全性均较为理想。
作者 杜桂贤
出处 《当代医药论丛》 2018年第18期154-155,共2页
  • 相关文献

参考文献3

二级参考文献31

  • 1Van Rhee F,Anaissie E,Angtuaco E,et al.Williams hematology[M].8th ed.New York,NY:McGraw Hill,2010:1279-1304.
  • 2Varettoni M,Corso A,Pica G,et al.Incidence,presenting features and outcome of extramedullary disease in multiple myeloma:a longitudinal study on 1 003consecutive patients[J].Ann Oncol,2010,21:325-330.
  • 3Weinstock M,Ghobrial IM.Extramedullary multiple myeloma[J].Leuk Lymphoma,2013,54:1135-1141.
  • 4Rajkumar SV,Blood E,Vessole D,et al.Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the eastern cooperative oncology group[J].J Clin Oncol,2006,24:图4 EMD患者不同治疗方案间的OS比较431-436.
  • 5Dimopoulos M,Spencer A,Attal M,et al.Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma[J].N Engl J Med,2007,357:2123-2132.
  • 6Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J].N Engl J Med,2005,352:2487-2498.
  • 7Attal M,Harousseau JL,Stoppa AM,et al.A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome[J].N Engl J Med,1996,335:91-97.
  • 8Barlogie B,Smallwood L,Smith T,et al.High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma[J].Ann Intern Med,1989,110:521-525.
  • 9Papanikolaou X,Repousis P,Tzenou T,et al.Incidence,clinical features,laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse[J].Leuk Lymphoma,2013,54:1459-1464.
  • 10Gkotzamanidou M,Kastritis E,Gavriatopoulou MR,et al.Increased serum lactate dehydrogenase should be included among the variables that define very-highrisk multiple myeloma[J].Clin Lymphoma Myeloma Leuk,2011,11:409-413.

共引文献38

同被引文献34

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部